Related Experiment Video

Updated: Jun 17, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Molecular diagnosis and therapy of kidney cancer

W Marston Linehan1, Gennady Bratslavsky, Peter A Pinto

  • 1Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA. WML@nih.gov

Annual Review of Medicine
|January 12, 2010
PubMed

Insights

Kidney cancer comprises various subtypes, fundamentally a metabolic disorder driven by distinct genes. Understanding these genetic pathways, like VHL, MET, and BHD, is crucial for developing targeted therapies and improving patient management.

Area of Science:

  • Oncology
  • Genetics
  • Metabolic Disorders

Background:

  • Kidney cancer is a heterogeneous disease with diverse genetic underpinnings.
  • Genetic studies reveal kidney cancer is fundamentally a metabolic disorder.
  • Specific genes (VHL, MET, BHD) are linked to distinct kidney cancer subtypes.

Purpose of the Study:

  • To explore the genetic basis of kidney cancer.
  • To understand the implications of genetic discoveries for diagnosis and management.
  • To highlight the development of targeted therapeutics based on genetic pathways.

Main Methods:

  • Review of genetic studies on kidney cancer.
  • Analysis of gene-specific pathways (VHL, MET, BHD).
  • Examination of molecular mechanisms and therapeutic implications.

Main Results:

  • VHL gene mutations are key in clear cell kidney cancer, leading to targeted therapies.
  • MET gene mutations are implicated in papillary renal carcinoma, with ongoing clinical trials.
  • BHD gene mutations are associated with chromophobe kidney cancer, linked to energy sensing pathways.
  • Inactivation of Krebs cycle enzymes due to mutations causes hereditary leiomyomatosis renal cell carcinoma.

Conclusions:

  • Understanding kidney cancer genetics provides insights into its metabolic nature.
  • Genetic knowledge facilitates improved diagnosis and personalized management strategies.
  • Targeted therapies based on specific gene mutations are revolutionizing kidney cancer treatment.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...